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Rationale
 Evidence treatment gaps for CVD prevention and 
management 
 Briganti et al, 2003; Simons et al, 2008; Simons et al, 1996; 
Janus, 2007 #273; Greater Green Triangle University 
Department of Rural Health, 2006
 Barriers to GPs delivering preventive health
 Evolving role of community pharmacist (CP)
Aim of research
 To establish frequency of contact with general 
practitioners (GPs) and community pharmacists 
(CPs) by patients with uncontrolled CVD risk factors. 
Setting
 Wimmera, Victoria
 Rural, farming area
Methods
 Electoral roll age/sex random sample from 
Wimmera  aged 25-84 years 
 GGT Risk factor studies previously described
 723/1425 (49%) participated (final sample = 694)
 Specific questions on GP and CP use:
 How many times have you visited a GP in the past 12 
months?
 How many times have you visited a CP for health reasons in 
the past 12 months?
 Age-standardised presentation of results
Data collection
 1. Self-completed 
questionnaire
 Demographics
 Use of health 
services
 Medical history
 Medicines used
 Diet and alcohol
 Smoking
 Physical activity
 2. Anthropometric 
and laboratory 
measurements
 Blood pressure
 Cholesterol
 Fasting blood 
glucose
 Body Mass Index 
(BMI)
 Waist and hip 
measurement
Results
 Overall average 4.6 GP visits vs. 6.0 CP 
visits/annum
GP and CP visiting crossovers
CP visits
GP visits 0 1+ Total
0 8.4% (25.2%)
(72.9%)
3.1% (4.7%)
(27.1%)
11.5%
1+ 24.9% (74.8%)
(28.1%)
63.6% (95.3%)
(71.9%)
88.5%
Total 33.3% 66.7% 100% 0
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Diet quality
GP visits CP visits
Correlation p-value Correlation p-value
Healthy food 0.098 0.114 0.133 <0.001
Convenience food
(≤1 missing)
-0.095 0.017 -0.116 <0.001
Discussion
 Frequent opportunities for intervention in pharmacy, 
especially:
 High or very high overall risk (primary onset)
 Uncontrolled diabetes, pre-diabetes
 Growing evidence for Australian CP involvement in 
multiple risk factor detection and management (Mc 
Namara et al, 2009; Emerson et al 2007; Krass et al, 
2006; Clifford et al, 2005; Hourihan et al, 2003)
 But what happens during routine care?
Implications for practice
 Collaboration required - limited interaction in 
current CP-GP programs
 Electronic records?
 Routine pharmacy practice for awareness and 
screening messages
 Currently underused?
 Incentives?
 Medicare items for CP CVD services?
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